Kymera Therapeutics posts $132 million Q3 loss, zero revenue and unveils strong Phase 1 data for IRF5 degrader KT‑579
+2 new sources since this summary was written
Kymera Therapeutics reported third‑quarter 2026 results on Oct. 29, 2026. The company posted a net loss of $132 million, or $(1.32) per diluted share, and revenue of $0, down from $2.8 million a year earlier. Cash and equivalents stood at about $1.6 billion, giving a runway into 2029. In the same filing the firm disclosed Phase 1 healthy‑volunteer data for its IRF5 degrader KT‑579, showing median target engagement of 90 % or greater and deep biomarker reductions.
Why it matters
The loss miss of $0.05 per share versus estimates signals continued cash burn despite a strong cash position, which may affect short‑term financing needs. The robust Phase 1 data for KT‑579 could de‑risk the IRF5 program and support upcoming Phase 1b lupus trials, potentially adding value to the pipeline.
Key facts
- 1Net loss for Q3 2026 was $132.0 million, compared with $82.2 million in the prior‑year quarter. tradingview.com
- 2GAAP diluted EPS was $(1.32) for the quarter, missing consensus by $0.05 per share. seekingalpha.com
- 3Revenue for the quarter was $0, versus $2.8 million in the year‑ago quarter. tradingview.com
- 4Cash, cash equivalents and marketable securities totaled approximately $1.6 billion as of Sep. 30, 2026. investing.com
- 5Phase 1 trial of KT‑579 achieved median IRF5 degradation of 90 % or greater across almost all dose levels. investing.com
- 6KT‑579 Phase 1 data showed median inhibition of IFNβ by 98 % at Day 14. investing.com
Summary written by AlphAI AI Desk from 8 of 8 sources. Not investment advice. Figures are as stated by the linked sources.